EphA2.ΔC also possesses the advantage of maintaining expression of the EphA2 extracellular domain, allowing us to disrupt forward signaling through the receptor on tumor cells, while minimizing the effects of potential bidirectional/reverse signaling through ligand‐expressing cells in the bone microenvironment. This evidence concerns the gene EPHA2 and neoplasm.